-
公开(公告)号：US20240165224A1
公开(公告)日：2024-05-23
申请号：US18283516
申请日：2022-03-25
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA , UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventor： Ventzislav Bojidarov VASSILEV , Corey MALLETT , Ronan ROUXEL , Normand BLAIS , Masaru KANEKIYO , Barney S. GRAHAM
IPC: A61K39/39 , A61K39/00 , A61K39/145 , A61P31/16 , A61P37/04
CPC classification number: A61K39/39 , A61K39/145 , A61P31/16 , A61P37/04 , A61K2039/55566 , A61K2039/6031
Abstract: The present invention relates to influenza virus immunisation using at least one influenza HA stem polypeptide in conjunction with squalene emulsion adjuvants, and to related aspects.
-
公开(公告)号：US20240181038A1
公开(公告)日：2024-06-06
申请号：US18283632
申请日：2022-03-25
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA , UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventor： Ventzislav Bojidarov VASSILEV , Corey MALLETT , Ronan ROUXEL , Normand BLAIS , Masaru KANEKIYO , Barney S. GRAHAM
IPC: A61K39/145 , A61K39/00 , A61K39/385 , A61P31/16 , C07K14/005
CPC classification number: A61K39/145 , A61K39/385 , A61P31/16 , C07K14/005 , A61K2039/53 , A61K2039/55555 , C12N2760/16122 , C12N2760/16134
Abstract: The present invention relates to a carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.
-
Patent Agency Ranking
公开(公告)号：US20240382583A1
公开(公告)日：2024-11-21
申请号：US18609504
申请日：2024-03-19
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Virginia AMMENDOLA , Babak BAYAT , Clarisse LORIN , Ventzislav Bojidarov VASSILEV , Alessandra VITELLI
Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.
-
公开(公告)号：US20220175910A1
公开(公告)日：2022-06-09
申请号：US17677141
申请日：2022-02-22
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Ventzislav Bojidarov VASSILEV
IPC: A61K39/145 , C07K14/005 , A61K39/12 , A61P31/16 , C12N15/62
Abstract: The present invention relates to novel influenza antigens, novel immunogenic or vaccine compositions, as well as to uses of and to methods for producing said antigens and compositions. In particular, the invention relates to recombinant forms of hemagglutinin (HA) and their use in vaccine compositions for the prevention of influenza virus infections.
-
公开(公告)号：US20210154290A1
公开(公告)日：2021-05-27
申请号：US16772194
申请日：2018-12-14
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Virginia AMMENDOLA , Babak BAYAT , Clarisse LORIN , Ventzislav Bojidarov VASSILEV , Alessandra VITELLI
IPC: A61K39/29 , C12N7/00 , C07K14/005 , A61K39/39 , A61P31/20
Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.
-
公开(公告)号：US20240181037A1
公开(公告)日：2024-06-06
申请号：US18283601
申请日：2022-03-25
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA , CUREVAC SE
Inventor： Hans Wolfgang GROßE , Edith JASNY , Janine MÜHE , Ventzislav Bojidarov VASSILEV , Clarisse LORIN , Nadia OUAKED , Corey MALLETT , Ronan ROUXEL , Normand BLAIS
IPC: A61K39/145 , A61K39/00 , A61P31/16 , A61P37/04
CPC classification number: A61K39/145 , A61P31/16 , A61P37/04 , A61K2039/53 , A61K2039/6018 , A61K2039/6031 , A61K2039/6093
Abstract: The present invention relates to carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.
-
公开(公告)号：US20210069322A1
公开(公告)日：2021-03-11
申请号：US16772203
申请日：2018-12-14
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Virginia AMMENDOLA , Babak BAYAT , Clarisse LORIN , Ventzislav Bojidarov VASSILEV , Alessandra VITELLI
Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
-
-
-
-
-
-
Search Results
7
records
(took 0.011 seconds)
